信达生物(01801.HK)将安维汀生物类似药之美加商业化权益授权予Coherus
信达生物(01801.HK)公布,与Coherus BioSciences达成一项合作协议,将集团的安维汀(贝伐珠单抗)生物类似药(IBI-305)在美国和加拿大的商业化权益授权给Coherus。Coherus计划於今年底至明年初向美国食品药品监督管理局递交生物制品许可证申请,具体时间取决於FDA审批进展,并在获批後开始商业化销售。
根据该协议条款,Coherus将就IBI-305支付集团首付款、里程碑付款4,500万美元。另外,基於IBI-305未来的销售情况,Coherus还将支付集团双位数百分比的销售分成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.